• VOD poised to replace traditional cable pay TV formats.
• Major Hollywood studio “streaming wars” have created an environment in which small film production companies like The Movie Studio can emerge as major brands.
• Company’s unique model includes creating films and distributing them on major SVOD platforms without the expense of using recognizable movie stars, thus increasing production quality and reducing capital expenditures.
• The Movie Studio has successfully monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on acquiring, developing, producing and distributing independent motion picture content for worldwide consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales and various media devices. The company is currently engaged in establishing its own OTT VOD platform to integrate both its own and aggregated feature film projects, television programming and other media intellectual properties. The Movie Studio is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and the company intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution.

The company has launched The Movie Studio App on Google Play and the App Store, enabling users to both view the company’s content and potentially become part of it. The app is in the completion stage, and The Movie Studio is conducting its final beta test of the app’s unique “audition submission” function, leveraging the company’s “Watch Our Movies, Be in Our Movies!” content platform and “Everyone’s a Star” campaign, which will be marketed via social media. Using the app, subscribers can upload a thumbnail photo of themselves along with a selfie video audition submission that showcases them reading character dialog. Audition submissions will then be reviewed by producers for possible participation of the auditionee in upcoming feature films.

The audition submission function provides the subscriber the ability to disrupt traditional motion picture casting and management, enabling access to participation in The Movie Studio’s independent motion picture and media content. At the same time, for the company this significantly reduces capital expenditures associated with those traditional media mechanisms. The Movie Studio’s unique business model capitalizes on the global demand for film content through the production and distribution of its own films while also providing opportunities for direct viewer involvement in its content.

The company operates using a growth-by-acquisition strategy that includes:

• Purchasing legacy film libraries.
• Upgrading acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the internet.
• Strategic partnerships and media content alignment with other OTT platforms and cross-collateralization of leverageable media assets for worldwide distribution.
• Producing micro-budget motion picture content with substantial production value utilizing new 4K technology and the company’s extensive legacy resources and unique production process, thereby significantly reducing capital expenditures while allowing for the potential of significant return on investment (ROI) with one successful production.
• Controlling its revenue streams through server-driven geo-fracturing global territories and its own OTT platform.

Currently, The Movie Studio is producing three upcoming feature films: “Cause and Effect,” “The Last Warhead” and “PEGASUS” — all with completed electronic press kits and pitch decks and fully produced motion picture-quality trailers ready for talent, distribution and financial integration.

The company has been successful in producing, casting and distributing its films on major SVOD platforms without recognizable stars, which reduces capital expenditures. However, The Movie Studio intends to integrate recognizable stars into the productions at value propositions either pre- or post-completion of the intellectual property.

Through successful beta testing, The Movie Studio has monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The company’s proposed server-based model will provide licensing payment from global territories without third-party distribution fees, which have traditionally been as high as 35%.

Founded in 1961 and formerly known as Destination Television, Inc., the company changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio is headquartered in Fort Lauderdale, Florida.

Cord-Cutting Creates Opportunity for VOD Players

Consumers are no longer content waiting for their favorite programming to come on the air – they expect instant streaming access where and how they want it. This has led to increased “cord cutting,” with consumers severing ties with their traditional pay TV providers in favor of digital streaming services.

With the advent of smart TVs with app integration, consumers can now watch what they want to watch when they want to watch it, fracturing traditional cable bundling mechanisms.

With pay TV usage steadily declining – satellite and cable TV businesses in the United States lost approximately 6 million customers in 2019 alone – streaming platforms are poised to potentially replace traditional pay TV distribution models altogether. Approximately 12,000 U.S. consumers are cutting the cord every day.

As this shift in media delivery continues and as digital devices become more sophisticated and bandwidth increases, VOD platforms have the potential to scale significantly. The Hollywood “streaming wars” of recent years have created an environment in which smaller competitors, like The Movie Studio, are able to emerge as major brands.

For more information, visit the company’s website at www.TheMovieStudio.com

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• Bolt Metals controls ownership of the 5,000-hectare Cyclops Nickel-Cobalt Project in Indonesia
• Company employs “minerals to market” strategy entailing successful bench scale scoping and drilling tests
• Strong results from large-scale 2019 exploration program identifying significant nickel horizons
• Robust, near-surface mineralization at project site

Mineral exploration company Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) works consistently toward carrying out its corporate strategy in 2020 as it continues to set ambitious milestones to create significant long-term shareholder value and become a leading international player in the electric vehicle battery metal sector. This includes preparations to commission and operate a pilot plant in Canada, which will contain an integrated circuit to produce high-purity nickel and cobalt strip solutions to develop battery-grade nickel and cobalt.

“2019 was a pivotal year for us, and we’re pleased to carry this momentum into 2020. Obtaining approval from Indonesia’s Ombudsman is an important step toward our goal of securing strategic partnerships and participating in Asia’s growing battery metals supply chain,” Ranjeet Sundher, CEO of Bolt Metals, stated in a news release (http://ibn.fm/dvEOe).

The company carried out large-scale exploration and development program at its flagship 5,000-hectare, Cyclops Nickel-Cobalt project, located in Papua Province, Indonesia last year. Drilling identified significant horizons of nickel mineralization, and bench-scale scoping tests yielded positive results for processing of this nickel material.

The flagship project, which has an environmental and mining permit issued, enjoys national, provincial, and local support. The project license is fully compliant with mining registration processes and will be transferred into a foreign investment license, where it will be administered by the central government.

Indonesia is the largest nickel producer on earth with a mandate to become a global superpower in the international EV and battery metals supply chain. Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to nickel-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

The usage of nickel in electric vehicle batteries has increased dramatically over the years due to its exceptional performance, longevity, and safety. The sharp increase in demand has forced Asian nations, particularly China as a leading EV manufacturer, to secure large supplies of the metal. Indonesia accounts for 25% of global nickel supply, making it a jurisdiction of choice for large nickel consumers, as well as nickel miners and processors.

To advance its focus on the EV supply chain, Bolt Minerals recently signed a non-binding cooperative agreement with Chinese tungsten and cobalt producer Hunan Jinxin¹. The agreement has two major components: Hunan Jinxin having purchasing rights over nickel sulphate and cobalt sulphate from the Cyclops Nickel-Cobalt Project or other Bolt Metals’ projects, and the possibility of purchasing equity in Bolt Metals or investing directly in the Cyclops Project.

With offices in Vancouver, Shanghai and Jakarta, and a team of international capital markets experts, Bolt Metals’ mandate is to acquire and develop production-grade battery metals opportunities throughout the Asia-Pacific region, and to become a key participant in China’s rapidly expanding electric vehicle supply chain. The company employs a vertically integrated “minerals-to-market” strategy to leverage these assets to their fullest.

For more information, visit the company’s website at www.BoltMetals.com

NOTE TO INVESTORS: The latest news and updates relating to PCRCF are available in the company’s newsroom at http://ibn.fm/PCRCF

¹ The agreement with does not imply that the Company has made a decision to proceed to production without first establishing mineral reserves. The Company has not made the decision to proceed to production and clarifies that any such statement if made in the future would be made in compliance with Companion Policy 43-101CP, 4.2(6) – Production Decision, which requires details of the significant risks associated with such a decision.

• ElevaciTEA addition to Elevacity nootropic line is vanilla-flavored chai ‘Happy Tea’ which offers potential weight management benefits
• Newest product’s two-day pre-sale overshadows prior launches
• Nootroopics may improve cognitive function, also offering potential health benefits like weight management, mood enhancement

As the energy drink craze is beginning to die down amid health concerns for the industry’s overly sugary and ultra-caffeinated reputation, consumers are searching for a healthier beverage to give their brains a boost. Enter nootropic beverages: the newest “smart drink” to hit the shelves has been met with an enthusiastic consumer response (http://ibn.fm/9bcYk). Sharing Services Global Corporation’s (OTCQB: SHRG) two-day pre-sale for its ElevaciTEA(TM) – a first-of-its-kind nootropic addition to the company’s functional beverage line – has illustrated consumers’ desire for the new category of functional beverages. The vanilla-flavored chai ‘Happy Tea’ offers potential health benefits such as weight management, cognitive function and mood enhancement.

“We continue to expand our functional beverage offerings and are pleased to report that the two day pre-sale of ElevaciTEA eclipsed any prior product launches,” Thatch noted in a news release (http://ibn.fm/k9lOV). “We will provide additional figures and performance in the near future.”

Offered on a “limited edition” basis from Sharing Services’ subsidiary Elevacity LLC, the nootropic addition targets increasing consumer demand for functional beverages with potential health benefits.

The launch of SHRG’s proprietary line of health and wellness products in 2017, through its Elepreneurs LLC and Elevacity Global LLC subsidiaries, was a milestone. The line consists of three categories – anti-aging skin care, functional beverages and natural supplements – and is consistent with the company’s emphasis on promoting health and happiness to both its growing team of Elepreneurs and their customers. The products are made with all-natural ingredients. Designed to trigger four hormones shown to promote happiness and well-being, referred to as D.O.S.E., the products promise to help consumers “elevate” their lives (http://ibn.fm/Eod1x). Since the initial launch of the proprietary line, SHRG has reported cumulative sales of $169 million.

SHRG is a Plano, Texas-based diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling through independent sales contractors as the sales force. Its divisions include Elevacity Global LLC, and Elepreneurs LLC. The company has announced global expansion plans.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Study reveals 77% of Americans interested in flexible, entrepreneurial options
• Ranking high on the list of “attractive entrepreneurial opportunities” was direct selling
• Flexibility, income potential at core of Sharing Services’ direct-selling opportunity

A new study released by the U.S. Direct Selling Association indicates that more than three-quarters of Americans are interested in flexible entrepreneurial opportunities (http://ibn.fm/uwJvU). That news bodes well for Sharing Services Global Corporation (OTCQB: SHRG), a diversified holding company that focuses on direct selling and offers its exclusive sales force – called Elepreneurs – an array of tools and resources to support them in their entrepreneurial careers.

The U.S. Direct Selling study was conducted by Ipsos, a global market research and a consulting firm. “The Consumer Attitudes & Entrepreneurship Study revealed that 77% of Americans are interested in flexible, entrepreneurial opportunities, with the most interest coming from young people,” Ipsos Executive Vice President Lisa Gudding stated in a news release. “We saw strong interest in both ‘gig’ work, such as ride-sharing services, as well as direct selling where people can share a variety of products in a face-to-face or online setting. These entrepreneurial opportunities also met several of the study participants’ top criteria, including ranking high for flexibility and ability to earn supplemental income.” The comprehensive study also confirmed positive perceptions of direct selling as both an attractive entrepreneurial opportunity and an ideally personalized and convenient way to “shop local.”

Among the 77% of Americans who expressed interest in entrepreneurship, the most interest came from younger generations, with 91% of Gen Z’s and 88% of Millennials interested in entrepreneurial opportunities. The study also reported that interest in pursuing an entrepreneurial opportunity was relatively equal among men (79%) and women (76%).

In addition, the research conducted revealed that, although U.S. unemployment rate is near a 50-year low, average wages have been sluggish over the same time period while household debt has increased. This imbalance has resulted in Americans searching for ways to earn supplemental income and increase financial security.

Ranking high on the list of “attractive entrepreneurial opportunities” was direct selling. Almost 80% of the survey responders indicated an interest in the industry, second only to gig work such as a ride-sharing service. Both types of entrepreneurial opportunities were seen as flexible and offering the ability to earn supplemental income.

Flexibility and income potential are certainly at the core of Sharing Services’ direct-selling opportunity. SHRG offers a line of proprietary health and wellness products that are shared by a growing international network of home-based entrepreneurs, or Elepreneurs. The company provides basic and advanced programs for both new and experienced entrepreneurs.

SHRG’s impressive independent sales force follows the company’s Blue Ocean selling strategy—an approach encouraging Elepreneurs to stop competing and instead focus on new markets and leads. In accordance with this strategy, Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

To help its sales force succeed in that strategy and enjoy flexibility and potential supplemental income, SHRG encourages its Elepreneurs to use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary, interactive video-data collection and analysis technology and provides next-generation customer-relationship-management, lead-generation, and video-marketing software applications.

Headquartered out of a 10,000-square-foot facility in Plano, Texas, SHRG has planned for future expansion. Customer-service facilities, operations and training rooms, and a video-production suite are currently available onsite with room for growth in each area. In addition, SHRG is looking forward to international expansion.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• New operating structure to drive efficiencies, support long-term growth
• SPRWF implements strategic measures to achieve leading in-store presence and makes representation at an individual store level top priority
• Positioned to offer investors high growth potential with strong liquidity position, recognized consumer brands and leading infrastructure

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is an innovator in the cannabis sector whose mission is to cultivate the world’s best cannabis and earn recognition as a leader in the global industry. By holding a global and diversified portfolio, the company has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies. The Toronto Stock Exchange symbol ‘FIRE’ is a testament to the passion for quality cannabis that drives the production of the company’s premium products.

Supreme Cannabis’s portfolio continues to grow as the company identifies new opportunities that align with its mission. The company has a high regard for its customers, who remain loyal to its brand’s distinguished premium product and value SPRWF’s respect for consumers’ product knowledge. SPRWF’s brands are backed by a strong collection of assets supporting key functions along its value chain – from cultivation, extraction, and manufacturing to R&D and product testing. SPRWF has taken crucial steps toward strengthening its impressive portfolio of assets and brands while scaling its strong Canadian business.

To support its plans for long-term growth and to drive efficiencies, Supreme Cannabis Company recently implemented a new operating structure. As part of this new structure, the company has expanded distribution of its 7ACRES brand through an enhanced retail-sales strategy and partnership with humble+fume Inc., one of North America’s leading distributors of cannabis accessories. Through this partnership, Supreme Cannabis plans to create the only sales force in Canada able to offer a complete solution of recreational cannabis brands and accessories to retailers.

“With the number of retail stores in Canada quickly growing and cannabis consumers making their purchase decisions in store, having representation at the individual store level provides an essential opportunity for our business to drive near-term revenue growth and support our transition to a cannabis CPG company,” Colin Moore, recently appointed director and interim president and CEO of Supreme Cannabis, stated in a news release (http://ibn.fm/5Kt5h). “Our partnership with humble+fume allows us to realize industry-leading sales coverage and focus our sales and marketing efforts at the most impactful stage of the cannabis consumer’s journey. We enter the second half of 2020 focused on the opportunity to address the Canadian market with competitive consumer brands supported by an unmatched sales force.”

To accelerate growth and support the company’s transformation into a leading cannabis company, SPRWF also recently changed leadership to align its expansion efforts with the skills and experience of key staff. In February, the board named Colin Moore interim president and CEO; a board director of Supreme Cannabis, Moore has previously served as president of Starbucks Coffee Canada and has a wealth of CPG experience.

In addition, the company announced several key operational hires to strengthen its executive team. John Griese has joined Supreme Cannabis as chief operating officer, Dan Sippel as general manager of 7ACRES and Sándor Wolkensperg as general manager of Supreme Cannabis Kitchener. Together, these operations experts bring significant experience to the team as Supreme Cannabis Company continues to expand its product portfolio and improve its operations (http://ibn.fm/Ec5U2).

Looking forward, the Supreme Cannabis Company is confident in its ability to continue delivering consistent, long-term shareholder value by maintaining its commitment to high standards and operational excellence.

The Supreme Cannabis Company is emerging as one of the world’s fastest-growing, premium plant-driven lifestyle companies by effectively deploying capital, with an emphasis on disciplined growth and high-quality products. Supreme Cannabis’ portfolio of brands (http://ibn.fm/MTIHa) caters to diverse consumer experiences, with brands and products that address recreational, wellness, medicinal and new consumer preferences. The company’s brand portfolio includes 7ACRES, Blissco, Truverra Inc., Sugarleaf by 7AC and Khalifa Kush Enterprises Canada. Supreme Cannabis’ brands are backed by a focused suite of world-class operating assets that serve key functions in the value chain, including scaled cultivation, value-add processing, centralized manufacturing and product testing and R&D (http://ibn.fm/B0QfE).

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• The streaming wars are allowing small competitors like The Movie Studio to capitalize on creatively designed digital business models
• The company implements a ‘Growth by Acquisition’ strategy, with significant purchases, resolution upgrades and remonetizing initiatives
• Innovative combination of ‘MovieSodes’ and digital ‘Audition Submission’ upload opportunities among elements propelling the company forward

As the advent of streaming wars changes the landscape of delivery of and demand for movie content, The Movie Studio Inc. (OTC: MVES) is emerging as a major brand in the industry. Despite its size as a small competitor, the company’s unique business model capitalizes on the increasing worldwide demand for movie content.

Formerly known as Destination Television, Inc. the company was founded in 1961 and changed its name to The Movie Studio Inc. in November 2012. The name is a nod to the first ‘Movie Studio’ in the United States built by Thomas Edison in 1893. Quite a long way from the circus and vaudeville actors performing for the camera back then, The Movie Studio Inc. is a vertically integrated motion picture production company that acquires, develops, produces, and distributes independent motion picture content for worldwide consumption in theatrical, video on demand (VOD), foreign sales, and through other various media devices.

In 2015, the company acquired assets of Seven Arts Entertainment, producer of motion pictures featuring top Hollywood stars including John Goodman, Ving Rhames, Burt Reynolds and Tim Robbins.

Propelling the company forward is its Growth by Acquisition strategy. The company is dedicated to the purchase of legacy film libraries, the overall resolution upgrade to 4K, and the re-monetizing of VOD streaming platforms across the internet with new film content. The Movie Studios’ latest releases are available on Showtime, Comcast and Amazon Prime.

The company’s revenue stream is powered by its digital business model, which includes motion picture aggregation and distribution, intended to create a direct server access platform of its content with “geo-fractured” territories for worldwide distribution.

The innovative production approach of the company is to film motion pictures in ten “chapters” and then edit them together to create the completed film. The chapters will be released via The Movie Studio’s App, currently available in the Apple App Store and the Google Play Store. These ‘MovieSodes’ create a stickiness to the App as a recurring revenue model.

In addition, the vertical integration of the company’s “Watch our Movies, Be in our Movies!” and “Everyone’s A Star” digital uploads are driving profitability. Users can upload a video, attach a thumbnail backdrop, download lines, submit their audition to the company for review by producers at The Movie Studio Inc. and be entered into consideration for a part in a movie.

As cord cutting becomes more common, streaming devices become more sophisticated and bandwidth increases, VOD has the potential to scale significantly. The commercial VOD technology now owned by The Movie Studio Inc. has efficient means of distribution, with the goal of increasing overall revenues for all parties in the motion picture production and distribution channels.

The technology exponentially improves upon the physical copy’s distribution format and eliminates piracy, revenue loss from copying, and video manipulation. The technology is also projected to increase revenues for producers and the related companies and could generate significant future re-occurring revenue for The Movie Studio Inc.

As major Corporations businesses shift to accommodate the market and new conditions globally leading some speculate that Hollywood will accelerate towards a streaming-only future ahead of schedule. Disney took steps in that direction when it recently released Frozen 2 (http://ibn.fm/tnKnG) on its Disney+ streaming service three months early, and moved up the digital release of Star Wars: The Rise of Skywalker (http://ibn.fm/CrkGJ). Now, Universal is making three of its movies (http://ibn.fm/v1L9g) available for on-demand viewing while they’re still playing in theaters… the ones that are still open, anyway. By the end of the week, The Invisible Man, The Hunt and Emma will be available to rent on digital platforms for $19.99 for a 48-hour window”. The implications for the future of the Movie Studio are obvious.

Further driving the company’s bottom line is the fact that The Movie Studio Inc. is the only major independent studio that manages its own in-house marketing and distribution department.

For more information, visit the company’s website at www.TheMovieStudio.com

• Major first-mover advantage in proprietary web-based e-commerce platform segment
• Penetrating U.S. independent pharmacy market with total purchases of $92 billion per annum
• Adding 100+ pharmacies per month to its online purchasing platform

Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and health care platform that offers health care buyers and sellers of pharmaceuticals procurement, currently has more than 11,900 pharmacies as registered users of its proprietary e-commerce platform. Registered users are under no contract of fee obligations when joining the ‘Supplier-to-Pharmacy’ (S2P) trading platform.

With the current number of users already on the network – serving an estimated 12 to 15 million patients indirectly through these member pharmacies , and adding about 100 new pharmacies per month, Trxade’s goal is to reach most, if not all, of the 24,000 independent pharmacies in the U.S., which have a combined annual purchasing power of more than $92 billion.

Leveraging a robust technology with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features, the platform is designed to help independent pharmacies identify the best available supplier prices for prescription drugs nationwide. The platform allows its members to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving them money by taking advantage of best purchase pricing.

This approach is part of Trxade’s efforts to be one of the driving forces behind a nationwide reduction of pharmaceutical and health care costs. To this end, the company is committed to developing its portfolio of products and services to drive value and growth for all members, employees and investors. Trading platform aside, Trxade also owns a mail order pharmacy and warehouse and drug delivery service through our Delivemeds (www.Delivmeds.com) and Bonum Health (www.BonumHealth.com) a Telehealth App.

The company recently launched a one-of-a-kind Telehealth initiative, called the ‘Bonum Health Hub’, together with wholly owned subsidiary Bonum Health, which partnered with Tampa Bay-based independent retail pharmacy chain Benzer Pharmacy. Bonum and Benzer will locate the Health Hubs in urban and rural areas lacking this type of care. The Hubs will provide capacities and technology to offer care to patients who can afford neither primary nor collaborative care.

The U.S. health care market is currently valued around $4 trillion. As the general population ages, further growth is expected, which in turn will have increasing impact on consumers as out-of-pocket expenses rise as well. Drug costs are expected to increase faster than overall health care costs and well above inflation. Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• Champignon Brands recently started trading on the Canadian Securities Exchange (CSE)
• The company also enters into definitive agreement to acquire Artisan Growers Ltd
• SHRM specializes in medicinal-mushroom, mushroom-infused products

Champignon Brands Inc. (CSE: SHRM), a wellness company specializing in the formulation and distribution of a group of artisanal-mushroom health supplements, recently began trading on the Canadian Securities Exchange (CSE). In February 2020, SHRM successfully completed an initial public offering (IPO) through lead agent PI Financial Corp. Additionally, Champignon Brands will look to secure a listing on the Frankfurt Stock Exchange and a quotation on the OTC Marketplace in the United States as soon as is feasible (http://ibn.fm/SzJuo).

“We’ve been assembling a dedicated roster of mycologists and health and wellness professionals to formulate several distinctive lines of premium fungi extracts,” Champignon CEO Gareth Birdsall stated in a news release. “The overall product portfolio is tailored for conscious consumers looking to support mental health and bolster cognitive performance through medicinal mushroom-based products.”

As Champignon Brands continues to bolster its product portfolio, the company also recently announced that it entered into a definitive agreement to acquire Artisan Growers Ltd., a British-Columbia-based, craft-mushroom cultivator and supplier. Champignon’s plan is to integrate Artisan Growers’ craft-mushroom production capacity into its existing medicinal-mushroom manufacturing, formulation and distribution infrastructure.

Champignon Brands’ focus is to continue to control its supply chain directly to the end user (http://ibn.fm/LLtPq). Artisan Growers operates a craft-mushroom cultivation facility that can produce an array of organic craft mushroom varietals including lion’s mane, chaga, reishi and agaricus blazei.

SHRM’s dedication is to the cultivation, distribution and proliferation of artisanal-medical mushrooms and associated CPGs (Consumer Packaged Goods). The company crafts its increasingly evolving portfolio with the health-conscious consumer in mind, as evidenced by its flagship brand, Vitality Superteas. A vertically integrated producer of medicinal mushrooms and related products, Champignon Brands is based in Vancouver, British Columbia.

With a passion for transforming conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, SHRM and its offerings align with the medical research community’s renewed interest in mushrooms’ health benefits. “Mushrooms contain protein, vitamins, minerals, and antioxidants. These can have various health benefits,” reported a recent Medical News Today article titled ‘What is the Nutritional Value of Mushrooms?’ (http://ibn.fm/Q7xCB). The article also states that “the antioxidant content in mushrooms may help prevent lung, prostate, breast and other types of cancer, according to the National Cancer Institute.” Harnessing the power of the humble mushroom, Champignon Brands is helping to shape the health and wellness product landscape. Champignon Brands has its premium family of organic, sustainable, vegan and non-GMO (genetically modified organisms) mushroom and mushroom-infused formulations. The company’s Vitality Superteas products includes Nourish Force Supertea, a blend of reishi tyobus tea mix; Mighty Recharge Supertea, created with lion’s mane tropical green ginseng tea mix; and Brain Enhance Supertea, a blend of cordycep hibiscus and berries tea mix.

Aside from its impressive product lineup, the company also has its research and development/product formulation partnership. Champignon and Drip Coffee Social Ltd. entered into this partnership to facilitate Drip Coffee Social infusing Champignon’s proprietary, mushroom-extract blend into a suite of cold-brew coffee products and signature in-house formulations (http://ibn.fm/86VgL). Champignon sees considerable potential in the CPG space.

The expectation is that the worldwide, functional-food marketplace that the company is working to enter will reach $34.3 billion by 2024. For 2020, Champignon Brands’ strategy includes the development of cGMP (Current Good Manufacturing Practice) formulations of bioactive compounds extracted from plants and fungi (http://ibn.fm/Z9gd7).

Champignon Brands is aggressively pursuing its mission of researching and distributing premium-medicinal, mushrooms-infused products. Of note to investors is that the company is targeting high-margin markets and optimizing its e-commerce and fulfillment infrastructure. Champignon Brands continues to promote the health and wellness benefits of functional mushrooms while at the same time offering the potential for significant investor return on investment.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

• Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases
• Predictive Oncology launches new AI platform in fight against new pathogens
• Artificial intelligence likely to help find COVID-19 vaccines and therapeutics

With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) just announced it was entering the fight against the latest scourge and is launching a new artificial intelligence platform to aid in vaccine and drug development to battle coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) (http://ibn.fm/BhOzX).

Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates.

“The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development,” HSC(TM) co-inventor Dr. Larry DeLucas stated in a news release (http://ibn.fm/xPLzZ). DeLucas, who flew aboard NASA Space Shuttle mission STS-50 as a payload specialist, is now the director of the Center for Structural Biology at University of Alabama School of Medicine.

Global health experts predict an ever-increasing number of viral outbreaks like COVID-19, and POAI intends to be at the forefront of efforts to identify and aid in the development of new vaccines and therapeutics. Predictive Oncology has enjoyed a business relationship with InventaBioTech and through negotiations signed a letter of intent to acquire Soluble Therapeutics, its assets and, most importantly, its HSC(TM) Technology. The technology dovetails POAI’s efforts against cancer as the HSC(TM) machines can be used in the development of new cancer antibodies and vaccines and create new possibilities in the fight against new pathogens. Soluble Therapeutics has previously worked with many of the major pharmaceutical companies searching for a vaccine such as Gilead Sciences (NASDAQ: GILD), GlaxoSmithKline (NYSE: GSK), Pfizer, Bayer and others.

The HSC(TM) Instrument and underlying technology have been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.

The HSC(TM) Technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. Able to do more with less, the technology only requires milligrams of material, where a traditional formulation effort can require up to a gram. Two decades in the making, HSC Technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pathogens, battle cancers, and enhance the drug development process by rapidly optimizing protein solubility and stability. Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics’ technology directly addresses this obstacle.

Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a rapid AI discovery platform that quickly and cost-effectively identifies potential vaccines and therapeutic candidates as well as optimizing protein formulations for stability and higher protein concentrations using FDA approved ingredients.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• CIIX concentrating on multi-pronged growth strategy
• The company operates a top financial-information website, developing CBD initiatives
• CIIX offers investors unique, contemporary ROI opportunities

A fintech enterprise, ChineseInvestors.com Inc. (OTCQB: CIIX) is focusing on its original mission of providing financial information and services to the larger Chinese community in the United States and globally. CIIX has become a leading financial-information website (in Chinese language character sets) for Chinese-speaking investors in the United States and China and continues to pursue new areas for growth in other industries as well (http://ibn.fm/TBCJS).

Via its website, www.ChineseInvestors.com, CIIX offers an array of investor-education products and services. Additionally, the company has recognized exceptional opportunities in the global cannabis industry. Established in 1999, ChineseInvestors.com has its corporate headquarters in San Gabriel, California, with offices in Flushing, New York, and Shanghai, China (http://ibn.fm/RzkQ8).

At the heart of CIIX’s financial information and services is its ChineseInvestors Method. This method is an inventive combination of a disciplined investing process, web-based tools, personalized instructions and invaluable support. The company’s investor-education products and services include real-time market commentary and analysis as well as educational-related services. CIIX also offers consultative services to smaller private companies considering becoming a public company and advertising- and public-relations-related support services.

Moreover, CIIX is laying the foundation to leverage the increasing demand for cannabidiol (CBD)-based nutrition and health products through its wholly owned foreign enterprise, CBD Biotech. Part of a burgeoning contemporary trend, the company is working to be a recognized leader in the hemp-based, CBD-oil industry. According to a Jan. 8 Research and Markets article, a minimum of 190 companies in China include industrial cannabis in their business scope (http://ibn.fm/MXfom).

The article also noted that CBD will become the emphasis for the development of the cannabis industry in China in the future. Nonetheless, industrial cannabis is not yet legal for medical applications in China. Consequently, the market is underdeveloped, resulting in low use of industrial cannabis.

The article further explains that as more thorough research is conducted in the field of cannabis, the marketplace for CBD extracts is growing. As that occurs, the application of CBD in food, cosmetics and health products will continue to multiply.

The dynamic CBD industry is a rising market expected to reach $2.1 billion in consumer sales this year. Furthermore, BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will exceed $20 billion by 2024 (http://ibn.fm/p9O4m). BDS Analytics predicts that most CBD product sales will take place in general retail stores instead of cannabis dispensaries.

Astute investors may do well to note how CIIX is well-positioned for growth in this market sector. The company has established a three-year development plan to leverage the merging of CBD and the nutrition with health products market in mainland China. In this marketplace, the benefits of CBD oil have not been broadly recognized.

Based on this wholesale agreement/development plan with a reputable CBD health brand, CIIX initiated the first-ever online, CBD-health products store published in the Chinese language, www.ChineseCBDoil.com. The company sells CBD-infused products both in-store and online. The company’s website caters to an increasing number of Chinese people who are coming to understand the manifold potential health benefits of CBD oil for the treatment of an assortment of conditions, including anxiety, stress, poor sleep, Alzheimer’s disease and other conditions.

ChineseInvestors.com continues to emphasize its two quality revenue channels for sales and profit growth: fintech products and services and CBD programs. Investors may note that in June 2019, the company anticipated the doubling of sales over next 12 months (http://ibn.fm/wyBYE). Also, CIIX is planning an IPO of CBD Biotech early this year. The path ahead looks promising for CIIX along with its visionary management team, customers and investors.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX